SHM's Clinical Quick Talks-Updates in Steatotic Liver Disease: MASLD and MASH

Pdf Summary

The document discusses updates in steatotic liver disease, highlighting the changes in nomenclature with the introduction of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). MASLD replaces NAFLD to better describe a condition driven by cardiometabolic risk factors, with MASLD progressing to MASH and eventually cirrhosis if untreated. Diagnosis of MASLD involves hepatic steatosis and cardiometabolic factors, while MASH includes evidence of hepatocellular injury, fibrosis, and inflammation. Treatment focuses on lifestyle modifications, diet, and exercise, with limited targeted therapies available for MASH. Complications of steatotic liver disease include an increased risk of diabetes, CKD, cirrhosis, and hepatocellular carcinoma. The document also covers the clinical stages of MASH, methods of diagnosis such as liver biopsy and non-invasive imaging techniques, and highlights key clinical pearls regarding cirrhosis, lean MAFLD, and dietary considerations in hepatic encephalopathy management. Lastly, it emphasizes the importance of early detection and intervention in managing steatotic liver disease to prevent disease progression and associated complications.

Asset Subtitle

Kimberly Tena Diaz, Alexander Garcia, Avneet Singh, Jonah Landau, Sabrina Gordon

Keywords

Steatotic liver disease

Metabolic dysfunction-associated steatotic liver disease

MASLD

Metabolic dysfunction-associated steatohepatitis

MASH

NAFLD

Hepatic steatosis

Cardiometabolic factors

Cirrhosis

Hepatocellular carcinoma